The medical community is excited by retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant results in preliminary studies . This compound works by replicating natural hormones to impact appetite and increase feelings of fullness , ultimately leading noticeable weight reduction . While currently under review and not broadly avail